Castle (CSTL) Q2 Revenue Tops Estimates

Castle Biosciences (CSTL) reported a mixed Q2 2025, significantly exceeding analyst estimates with GAAP EPS of $0.15 and non-GAAP revenue of $86.2 million, though revenue was nearly flat year-over-year. While core test volumes, particularly TissueCypher, showed strong growth, GAAP net income nearly halved and gross margin declined due to significant reimbursement setbacks for tests like DecisionDx-SCC and the discontinuation of IDgenetix. However, driven by strong adoption of key tests, management raised full-year 2025 revenue guidance to $310-$320 million, indicating a strategic focus on high-growth, reimbursable offerings.

Analysis

Castle Biosciences (CSTL) reported a bifurcated Q2 2025, characterized by significant beats on headline estimates alongside deteriorating underlying profitability. The company surpassed consensus with a GAAP EPS of $0.15 versus an expected loss of $0.53, and non-GAAP revenue of $86.2 million beat the $71.45 million forecast. However, these figures mask significant operational headwinds, as year-over-year GAAP revenue was nearly flat (down 0.9%), while GAAP net income was almost halved and adjusted EBITDA fell by over 51%. This profitability decline is directly linked to a gross margin contraction to 77.3% from 80.7% a year prior, driven by severe reimbursement setbacks. Specifically, Medicare ceased coverage for the DecisionDx-SCC test in April 2025, and the company discontinued its IDgenetix test due to persistent reimbursement challenges. In response, management is strategically pivoting, shifting resources to its core growth drivers: DecisionDx-Melanoma, which recently received FDA Breakthrough Device designation, and TissueCypher, which is experiencing rapid adoption. This strategic focus underpins the raised full-year 2025 revenue guidance to a range of $310-$320 million, signaling confidence that growth in these core areas will outweigh the revenue lost from discontinued and non-reimbursed tests.

Key Decisions for Investors

• Investors should monitor the execution of the company's strategic pivot, focusing on volume growth and reimbursement stability for core products DecisionDx-Melanoma and TissueCypher, as these are now the critical determinants of future performance.
• The raised revenue guidance must be carefully weighed against the significant year-over-year declines in gross margin and adjusted EBITDA; it is crucial to assess if the new product mix can generate sustainable profitability, not just top-line growth.
• The loss of Medicare coverage for a key test highlights a material risk related to payor decisions, warranting heightened scrutiny of any future coverage determinations for the company's remaining portfolio.
• Consider the stock a 'show-me' story where continued outperformance will depend on management's ability to demonstrate that growth from its core franchise can successfully offset the financial impact of lost revenue streams and rebuild margins.